From supply continuity to national resilience
Read the expanded working-paper draft, evidence notes and original publication record.
Read the full draft →
ENGAGE MSI An independent research and policy institute advancing medicines security, pharmaceutical resilience and global health policy.
Securing medicines.
Strengthening nations.
The Medicines Security Institute advances the systems, intelligence and international cooperation required to ensure that essential medicines remain safe, available and resilient in an age of geopolitical disruption and technological change.
01 — The imperative
Medicines are not merely products.
They are strategic infrastructure.
Shortages, concentrated production, fragile logistics, regulatory divergence, antimicrobial resistance and geopolitical competition have moved medicines security to the centre of national resilience.
MSI has begun research operations to define medicines security as a coherent interdisciplinary field—and to turn rigorous evidence into decision advantage for public institutions, industry and society.
02 — Research architecture
Ten domains.
One security system.
MSI studies medicines security across the full chain of national capability—from discovery and regulation to manufacturing, distribution, workforce, capital and future shocks.
03 — Flagship work
Building the field.
Equipping decisions.
Our initial portfolio establishes the concepts, analytical infrastructure and recurring intelligence products needed to make medicines security measurable and actionable.
01
MSI-SIS
Strategic Intelligence System
A decision architecture connecting evidence, indicators, scenarios and response options across all ten domains.
02
MSI-INDEX
Medicines Security Index
A comparative framework for assessing national capability, exposure and resilience.
03
FOUNDATIONS
Medicines Security Papers
A foundational series defining the discipline, its evidence base and implications for public leadership.
04 — Strategic advisory
Independent intelligence for
high-consequence decisions.
MSI translates interdisciplinary research into carefully scoped policy and executive formats. Engagements are designed around institutional need, evidence quality and public-interest safeguards.
01
Governments & health systems
National strategy, capability assessment, policy design and executive briefings.
02Pharmaceutical leaders
Supply-chain resilience, geopolitical exposure, manufacturing strategy and organisational readiness.
03Investors & institutions
Decision-relevant intelligence on strategic capacity, dependencies, technology and capital.
04Scholars & researchers
A rigorous interdisciplinary platform for original research, visiting appointments and global exchange.
Strategic reviews Policy laboratories Executive briefings Research partnerships
05 — Institutional integrity
Credibility must be
constitutional.
MSI’s research operations are guided by independence, scholarly rigour, responsible funding and public accountability. Its formal legal status, governing bodies and approved charters will be published as they are established and verified.
Governance charterClear authority, fiduciary responsibility, oversight and succession.
Research integrityPublished methods, evidence limits, corrections and author disclosures.
Funding independenceNo funder control over findings, publication or editorial decisions.
Scholarly excellenceGlobal fellowships, peer exchange and multidisciplinary collaboration.
Institution-led governance
Independent oversight. Accountable delivery.
MSI's governance framework connects governing-board stewardship, scientific and international advice, and accountable executive delivery. Appointments will be announced following confirmation.
06 — Work with MSI
Help shape a safer,
more resilient medicines future.
We welcome serious dialogue with governments, international institutions, pharmaceutical leaders, research organisations, funders and scholars whose work aligns with MSI’s public-interest mission.
Initiate a confidential conversation Research collaboration · Strategic commissions · Institutional funding · Scholarly appointmentsLatest research · October 2026
Evidence you can explore.
From architecture to evidence
Our first editorial briefing sets out the decisions and research priorities behind the programme.
Read MSI Outlook →Making medicines security measurable
Explore the draft Index protocol and evidence-register prototype.
Explore the methodology →